{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:32:32Z","timestamp":1793277152933,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-025-03202-8","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:35:42Z","timestamp":1755794142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["LC-ESI-HRMS-Based Evaluation of Antioxidants as Additives to Inhibit Genotoxic Nitrosamine Formation in Metformin Hydrochloride Tablets"],"prefix":"10.1208","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7673-8229","authenticated-orcid":false,"given":"Aishwarya","family":"Dande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4850-6783","authenticated-orcid":false,"given":"Nikhil","family":"Pallaprolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4967-9349","authenticated-orcid":false,"given":"Sangita","family":"Gadilohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7528-6996","authenticated-orcid":false,"given":"Sushmita","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1435-6115","authenticated-orcid":false,"given":"Rajkumar","family":"Malayandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2189-2234","authenticated-orcid":false,"given":"Subramanian","family":"Natesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8185-3483","authenticated-orcid":false,"given":"Abhishek","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8946-5423","authenticated-orcid":false,"given":"Murali","family":"Kumarasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7820-9486","authenticated-orcid":false,"given":"Ravichandiran","family":"Velayutham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1932-637X","authenticated-orcid":false,"given":"Ramalingam","family":"Peraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"3202_CR1","doi-asserted-by":"publisher","first-page":"108864","DOI":"10.1016\/j.celrep.2021.108864","volume":"34","author":"JE Kay","year":"2021","unstructured":"Kay JE, Corrigan JJ, Armijo AL, Nazari IS, Kohale IN, Torous DK, et al. Excision of mutagenic replication-blocking lesions suppresses cancer but promotes cytotoxicity and lethality in nitrosamine-exposed mice. Cell Rep. 2021;34:108864.","journal-title":"Cell Rep"},{"key":"3202_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0165-1218(91)90123-4","volume":"259","author":"AR Tricker","year":"1991","unstructured":"Tricker AR, Preussmann R. Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential. Mutat Res\/Genet Toxicol. 1991;259:277\u201389.","journal-title":"Mutat Res\/Genet Toxicol"},{"key":"3202_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2628(08)60336-5","volume":"22","author":"NT Crosby","year":"1976","unstructured":"Crosby NT, Sawyer R. N-nitrosamines: a review of chemical and biological properties and their estimation in foodstuffs. Adv Food Res. 1976;22:1\u201371.","journal-title":"Adv Food Res"},{"key":"3202_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0048-9697(79)90069-X","volume":"13","author":"L Fishbein","year":"1979","unstructured":"Fishbein L. Overview of some aspects of occurrence, formation and analysis of nitrosamines. Sci Total Environ. 1979;13:157\u201388.","journal-title":"Sci Total Environ"},{"key":"3202_CR5","doi-asserted-by":"publisher","first-page":"121687","DOI":"10.1016\/j.ijpharm.2022.121687","volume":"618","author":"N Golob","year":"2022","unstructured":"Golob N, Grahek R, Ross M, Ro\u0161kar R. Nitrocellulose blister material as a source of N-nitrosamine contamination of pharmaceutical drug products. Int J Pharm. 2022;618:121687.","journal-title":"Int J Pharm"},{"key":"3202_CR6","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.xphs.2022.12.022","volume":"112","author":"S Horne","year":"2023","unstructured":"Horne S, Vera MD, Nagavelli LR, Sayeed VA, Heckman L, Johnson D, et al. Regulatory experiences with root causes and risk factors for nitrosamine impurities in pharmaceuticals. J Pharm Sci. 2023;112:1166\u201382.","journal-title":"J Pharm Sci"},{"key":"3202_CR7","doi-asserted-by":"publisher","unstructured":"Shaikh T. Nitrosamine impurities in drug substances and drug products (January 1, 2020). https:\/\/doi.org\/10.5281\/zenodo.3629095.","DOI":"10.5281\/zenodo.3629095"},{"key":"3202_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jsps.2022.12.010","volume":"31","author":"W Wichitnithad","year":"2023","unstructured":"Wichitnithad W, Nantaphol S, Noppakhunsomboon K, Rojsitthisak P. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals. Saudi Pharm J. 2023;31:295\u2013311.","journal-title":"Saudi Pharm J"},{"key":"3202_CR9","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1016\/j.xphs.2021.04.021","volume":"110","author":"B Tuesuwan","year":"2021","unstructured":"Tuesuwan B, Vongsutilers V. Nitrosamine contamination in pharmaceuticals: threat, impact, and control. J Pharm Sci. 2021;110:3118\u201328.","journal-title":"J Pharm Sci"},{"key":"3202_CR10","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.xphs.2022.11.013","volume":"112","author":"J Schlingemann","year":"2023","unstructured":"Schlingemann J, Burns MJ, Ponting DJ, Avila CM, Romero NE, Jaywant MA, et al. The landscape of potential small and drug substance related nitrosamines in pharmaceuticals. J Pharm Sci. 2023;112:1287\u2013304.","journal-title":"J Pharm Sci"},{"key":"3202_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0041-008X(75)90255-0","volume":"31","author":"SS Mirvish","year":"1975","unstructured":"Mirvish SS. Formation of N-nitroso compounds: chemistry, kinetics, and in vivo occurrence. Toxicol Appl Pharmacol. 1975;31:325\u201351.","journal-title":"Toxicol Appl Pharmacol"},{"key":"3202_CR12","doi-asserted-by":"publisher","first-page":"114677","DOI":"10.1016\/j.jpba.2022.114677","volume":"213","author":"J Jire\u0161","year":"2022","unstructured":"Jire\u0161 J, Dou\u0161a M. Nitrites as precursors of N-nitrosation in pharmaceutical samples\u2013A trace level analysis. J Pharm Biomed Anal. 2022;213:114677.","journal-title":"J Pharm Biomed Anal"},{"key":"3202_CR13","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1021\/acs.oprd.0c00323","volume":"24","author":"R L\u00f3pez-Rodr\u00edguez","year":"2020","unstructured":"L\u00f3pez-Rodr\u00edguez R, McManus JA, Murphy NS, Ott MA, Burns MJ. Pathways for N-nitroso compound formation: secondary amines and beyond. Org Process Res Dev. 2020;24:1558\u201385.","journal-title":"Org Process Res Dev"},{"key":"3202_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.38212\/2224-6614.1133","volume":"29","author":"FS Aldawsari","year":"2021","unstructured":"Aldawsari FS, Alshehry YM, Alghamdi TS. N-nitrosodimethylamine (NDMA) contamination of ranitidine products: a review of recent findings. J Food Drug Anal. 2021;29:39.","journal-title":"J Food Drug Anal"},{"key":"3202_CR15","doi-asserted-by":"publisher","first-page":"11095","DOI":"10.1021\/es3023094","volume":"46","author":"RJ Le","year":"2012","unstructured":"Le RJ, Gallard H, Crou\u00e9 J-P, Papot S, Deborde M. NDMA formation by chloramination of ranitidine: kinetics and mechanism. Environ Sci Technol. 2012;46:11095\u2013103.","journal-title":"Environ Sci Technol"},{"key":"3202_CR16","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/cts.12995","volume":"14","author":"JA Wagner","year":"2021","unstructured":"Wagner JA, Dinh JC, Lightdale JR, Gold BD, Colombo JM. Is this the end for ranitidine? NDMA presence continues to confound. Clin Transl Sci. 2021;14:1197.","journal-title":"Clin Transl Sci"},{"key":"3202_CR17","unstructured":"US FDA. Mylan initiates voluntary nationwide recall of three lots of nizatidine capsules, USP, due to the detection of trace amounts of NDMA (N-Nitrosodimethylamine) impurity found in the active pharmaceutical ingredient manufactured by Solara active pharma Scien. Company Announcement. [Internet]. US Food and Drug Administration. 2020 [Accessed on 2024 Feb 11]. Available from: https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/mylan-initiates-voluntary-nationwide-recall-three-lots-nizatidine-capsules-usp-due-detection-trace"},{"key":"3202_CR18","unstructured":"US FDA. Amneal Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Nizatidine Oral Solution, 15 mg\/mL, Due to Potential Levels of N-nitrosodimethylamine (NDMA) Impurity Amounts Above the Levels Established by FDA [Internet]. US Food and Drug Administration. 2020 [Accessed on 2024 Mar 2]. Available from: https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-nizatidine-oral-solution-15-mgml-due"},{"key":"3202_CR19","unstructured":"US FDA. FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm\u2019s already recalled products [Internet]. US Food and Drug Administration. 2018 [Accessed on 2024 Apr 3]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-provides-update-its-ongoing-investigation-valsartan-products-and-reports-finding-additional"},{"key":"3202_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-019-1376-1","volume":"20","author":"NA Charoo","year":"2019","unstructured":"Charoo NA, Ali AA, Buha SK, Rahman Z. Lesson learnt from recall of valsartan and other angiotensin II receptor blocker drugs containing NDMA and NDEA impurities. AAPS PharmSciTech. 2019;20:1\u20136.","journal-title":"AAPS PharmSciTech"},{"key":"3202_CR21","unstructured":"US FDA. FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall [Internet]. US Food and Drug Administration. 2019 [Accessed on 2024 Apr 4]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-statement-fdas-ongoing-investigation-valsartan-and-arb-class-impurities-and-agencys-steps"},{"key":"3202_CR22","unstructured":"US FDA. FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan) [Internet]. US Food and Drug Administration. 2019 [Accessed on 2024 Dec 23]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan?utm_campaign=FDA%20updates%20on%20angiotensin%20II%20receptor%20blocker%20%28ARB%29%20recalls%3A%20ScieGen%E2%80%99s%20irbesartan%20recalled%20due&utm_medium=email"},{"key":"3202_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00508-021-01822-1","volume":"133","author":"B Sadasivam","year":"2021","unstructured":"Sadasivam B, Fatima Z, Atal S. Metformin recalls: regulatory background, concerns and challenges. Wien Klin Wochenschr. 2021;133:851\u20134.","journal-title":"Wien Klin Wochenschr"},{"key":"3202_CR24","doi-asserted-by":"publisher","first-page":"113877","DOI":"10.1016\/j.jpba.2020.113877","volume":"195","author":"J Jire\u0161","year":"2021","unstructured":"Jire\u0161 J, Kal\u00e1\u0161ek S, Gibala P, Rudovsk\u00fd J, Dou\u0161a M, Kubelka T, et al. Insight into the formation of N-nitrosodimethylamine in metformin products. J Pharm Biomed Anal. 2021;195:113877.","journal-title":"J Pharm Biomed Anal"},{"key":"3202_CR25","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.3390\/molecules25225304","volume":"25","author":"A Zmys\u0142owski","year":"2020","unstructured":"Zmys\u0142owski A, Ksi\u0105\u017cek I, Szterk A. N-nitrosodimethylamine contamination in the metformin finished products. Molecules. 2020;25:5304.","journal-title":"Molecules"},{"key":"3202_CR26","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1021\/acs.jmedchem.0c02120","volume":"64","author":"SS Bharate","year":"2021","unstructured":"Bharate SS. Critical analysis of drug product recalls due to nitrosamine impurities. J Med Chem. 2021;64:2923\u201336.","journal-title":"J Med Chem"},{"key":"3202_CR27","unstructured":"US FDA. Control of Nitrosamine Impurities in Human Drugs, Guidance for Industry [Internet]. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Pharmaceutical Quality\/Manufacturing Standards (CGMP). 2024 [Accessed on 2024 Apr 16]. Available from: https:\/\/www.fda.gov\/media\/141720\/download"},{"key":"3202_CR28","unstructured":"European Medicines Agency (EMA). Nitrosamine impurities in human medicinal products [Internet]. 2020 Jun. [Accessed on 2024 Apr 16] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/opinion-any-scientific-matter\/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf"},{"key":"3202_CR29","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1016\/j.xphs.2023.06.013","volume":"112","author":"D Shakleya","year":"2023","unstructured":"Shakleya D, Asmelash B, Alayoubi A, Abrigo N, Mohammad A, Wang J, et al. Bumetanide as a model NDSRI substrate: n-nitrosobumetanide impurity formation and its inhibition in bumetanide tablets. J Pharm Sci. 2023;112:3075\u201387.","journal-title":"J Pharm Sci"},{"key":"3202_CR30","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","volume":"27","author":"RC Cioc","year":"2023","unstructured":"Cioc RC, Joyce C, Mayr M, Bream RN. Formation of N-nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies. Org Process Res Dev. 2023;27:1736\u201350.","journal-title":"Org Process Res Dev"},{"key":"3202_CR31","unstructured":"US FDA. Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs) Guidance for Industry [Internet]. US Food and Drug Administration. 2024 [Accessed on 2024 May 22]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cder-nitrosamine-impurity-acceptable-intake-limits"},{"key":"3202_CR32","doi-asserted-by":"publisher","first-page":"121740","DOI":"10.1016\/j.ijpharm.2022.121740","volume":"620","author":"J Schlingemann","year":"2022","unstructured":"Schlingemann J, Boucley C, Hickert S, Bourasseau L, Walker M, Celdran C, et al. Avoiding N-nitrosodimethylamine formation in metformin pharmaceuticals by limiting dimethylamine and nitrite. Int J Pharm. 2022;620:121740.","journal-title":"Int J Pharm"},{"key":"3202_CR33","doi-asserted-by":"publisher","first-page":"8653","DOI":"10.1021\/es500997e","volume":"48","author":"YD Liu","year":"2014","unstructured":"Liu YD, Selbes M, Zeng C, Zhong R, Karanfil T. Formation Mechanism of NDMA from Ranitidine, Trimethylamine, and Other Tertiary Amines during Chloramination: A Computational Study. Environ Sci Technol. 2014;48:8653\u201363.","journal-title":"Environ Sci Technol"},{"key":"3202_CR34","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/14740338.2021.1917547","volume":"20","author":"NEH Nasr","year":"2021","unstructured":"Nasr NEH, Metwaly MG, Ahmed EO, Fares AR, ElMeshad AN. Investigating the root cause of N-nitrosodimethylamine formation in metformin pharmaceutical products. Expert Opin Drug Saf. 2021;20:855\u201362.","journal-title":"Expert Opin Drug Saf"},{"key":"3202_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1208\/s12249-023-02523-w","volume":"24","author":"NA Charoo","year":"2023","unstructured":"Charoo NA, Dharani S, Khan MA, Rahman Z. Nitroso Impurities in Drug Products: An Overview of Risk Assessment, Regulatory Milieu, and Control Strategy. AAPS PharmSciTech. 2023;24:60.","journal-title":"AAPS PharmSciTech"},{"key":"3202_CR36","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.envpol.2016.07.040","volume":"219","author":"RM Briones","year":"2016","unstructured":"Briones RM, Sarmah AK, Padhye LP. A global perspective on the use, occurrence, fate and effects of anti-diabetic drug metformin in natural and engineered ecosystems. Environ Pollut. 2016;219:1007\u201320.","journal-title":"Environ Pollut"},{"key":"3202_CR37","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","volume":"60","author":"CJ Bailey","year":"2017","unstructured":"Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60:1566\u201376.","journal-title":"Diabetologia"},{"key":"3202_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dom.15749","volume":"26","author":"GA Silverii","year":"2024","unstructured":"Silverii GA. Optimizing metformin therapy in practice: Tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes. Diabetes Obes Metab. 2024;26:42\u201354.","journal-title":"Diabetes Obes Metab"},{"key":"3202_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.15663","volume":"26","author":"CJ Bailey","year":"2024","unstructured":"Bailey CJ. Metformin: Therapeutic profile in the treatment of type 2 diabetes. Diabetes Obes Metab. 2024;26:3\u201319.","journal-title":"Diabetes Obes Metab"},{"key":"3202_CR40","doi-asserted-by":"publisher","first-page":"124832","DOI":"10.1016\/j.ijpharm.2024.124832","volume":"666","author":"D Shakleya","year":"2024","unstructured":"Shakleya D, Alayoubi A, Brown D, Mokbel A, Abrigo N, Mohammad A, et al. Nitrosamine mitigation: NDMA impurity formation and its inhibition in metformin hydrochloride tablets. Int J Pharm. 2024;666:124832.","journal-title":"Int J Pharm"},{"key":"3202_CR41","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1016\/j.xphs.2021.08.010","volume":"110","author":"KK Nanda","year":"2021","unstructured":"Nanda KK, Tignor S, Clancy J, Marota MJ, Allain LR, D\u2019Addio SM. Inhibition of N-nitrosamine formation in drug products: a model study. J Pharm Sci. 2021;110:3773\u20135.","journal-title":"J Pharm Sci"},{"key":"3202_CR42","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1021\/jf000147+","volume":"48","author":"T Rundl\u00f6f","year":"2000","unstructured":"Rundl\u00f6f T, Olsson E, Wiernik A, Back S, Aune M, Johansson L, et al. Potential nitrite scavengers as inhibitors of the formation of N-nitrosamines in solution and tobacco matrix systems. J Agric Food Chem. 2000;48:4381\u20138.","journal-title":"J Agric Food Chem"},{"key":"3202_CR43","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/jf980130f","volume":"46","author":"B Rousseau","year":"1998","unstructured":"Rousseau B, Rosazza JPN. Reaction of ferulic acid with nitrite: formation of 7-hydroxy-6-methoxy-1, 2 (4 h)-benzoxazin-4-one. J Agric Food Chem. 1998;46:3314\u20137.","journal-title":"J Agric Food Chem"},{"key":"3202_CR44","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1021\/jf00071a011","volume":"34","author":"KR Bharucha","year":"1986","unstructured":"Bharucha KR, Cross CK, Rubin LJ. P-Alkoxyanilines as antinitrosamine agents for bacon. J Agric Food Chem [Internet]. 1986;34:814\u20138. https:\/\/doi.org\/10.1021\/jf00071a011.","journal-title":"J Agric Food Chem [Internet]"},{"key":"3202_CR45","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1021\/jf60232a062","volume":"28","author":"KR Bharucha","year":"1980","unstructured":"Bharucha KR, Cross CK, Rubin LJ. Long-chain acetals of ascorbic and erythorbic acids as antinitrosamine agents for bacon. J Agric Food Chem. 1980;28:1274\u201381.","journal-title":"J Agric Food Chem"},{"key":"3202_CR46","doi-asserted-by":"crossref","unstructured":"Kikugawa K, Kato T. Proteins as scavengers of nitrite: antimutagenic implications. Antimutagenesis and Anticarcinogenesis Mechanisms III, Basic Life Sciences. 1993;61:65\u201385.","DOI":"10.1007\/978-1-4615-2984-2_6"},{"key":"3202_CR47","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/0278-6915(92)90196-R","volume":"30","author":"T Kato","year":"1992","unstructured":"Kato T, Kikugawa K. Proteins and amino acids as scavengers of nitrite: inhibitory effect on the formation of nitrosodimethylamine and diazoquinone. Food Chem Toxicol. 1992;30:617\u201326.","journal-title":"Food Chem Toxicol"},{"key":"3202_CR48","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.xphs.2023.03.022","volume":"112","author":"A-CV Bayne","year":"2023","unstructured":"Bayne A-CV, Misic Z, Stemmler RT, Wittner M, Frerichs M, Bird JK, et al. N-nitrosamine mitigation with nitrite scavengers in oral pharmaceutical drug products. J Pharm Sci. 2023;112:1794\u2013800.","journal-title":"J Pharm Sci"},{"key":"3202_CR49","unstructured":"US FDA. Updates on possible mitigation strategies to reduce the risk of nitrosamine drug substance-related impurities in drug products [Internet]. US Food and Drug Administration. 2021 [Accessed on 2024 Jan 11]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/updates-possible-mitigation-strategies-reduce-risk-nitrosamine-drug-substance-related-impurities"},{"key":"3202_CR50","doi-asserted-by":"publisher","first-page":"e9747","DOI":"10.1002\/rcm.9747","volume":"38","author":"D Aishwarya","year":"2024","unstructured":"Aishwarya D, Nikhil P, Natesan S, Velayutham R, Peraman R. Development and validation of high-performance liquid chromatography-Orbitrap mass spectrometric method for quantification of NDMA in ranitidine drug products and evaluation of antioxidants as inhibitors of classical nitrosation reaction. Rapid Commun Mass Spectrom. 2024;38:e9747.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"3202_CR51","unstructured":"USFDA. Control of Nitrosamine Impurities in Human Drugs Guidance for Industry, Revision 2 [Internet]. 2024 Sep. [Accessed on 2024 Jan 14] Available from: https:\/\/www.fda.gov\/media\/141720\/download"},{"key":"3202_CR52","doi-asserted-by":"publisher","first-page":"114872","DOI":"10.1016\/j.jpba.2022.114872","volume":"218","author":"J Jire\u0161","year":"2022","unstructured":"Jire\u0161 J, Dou\u0161a M, Gibala P, Kubelka T. N-Nitrosation in the absence of nitrosating agents in pharmaceuticals? J Pharm Biomed Anal. 2022;218:114872.","journal-title":"J Pharm Biomed Anal"},{"key":"3202_CR53","doi-asserted-by":"publisher","first-page":"114677","DOI":"10.1016\/j.jpba.2022.114677","volume":"213","author":"J Jire\u0161","year":"2022","unstructured":"Jire\u0161 J, Dou\u0161a M. Nitrites as precursors of N-nitrosation in pharmaceutical samples \u2013 A trace level analysis. J Pharm Biomed Anal. 2022;213:114677.","journal-title":"J Pharm Biomed Anal"},{"key":"3202_CR54","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.xphs.2023.03.007","volume":"112","author":"N Golob","year":"2023","unstructured":"Golob N, Peterlin S, Grahek R, Ro\u0161kar R. NDMA Formation Due to Active Ingredient Degradation and Nitrite Traces in Drug Product. J Pharm Sci. 2023;112:1277\u201386.","journal-title":"J Pharm Sci"},{"key":"3202_CR55","unstructured":"Jingyue Y, Tim M, Raghavi K, Wei Y, Cynthia S, Jason R, David K, LC-HRMS Based Analytical Platform to Determine Nitrosamines in Pharmaceuticals: Modern Analytical Techniques Meet Regulatory Needs, Center for Drug Evaluation and Research, 2021 FDA Science Forum, 2021. [Accessed on 2024 Jan 12]. Available from: https:\/\/www.fda.gov\/science-research\/fda-science-forum\/lc-hrms-based-analytical-platform-determine-nitrosamines-pharmaceuticals-modern-analytical"},{"key":"3202_CR56","unstructured":"US FDA. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of Six Nitrosamine Impurities in ARB Drugs [Internet]. US Food and Drug Administration. 2019 [Accessed on 2024 Jan 11]. Available from: https:\/\/www.fda.gov\/media\/125478\/download"},{"key":"3202_CR57","unstructured":"US FDA. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of NDMA in Ranitidine Drug Substance and Drug Product [Internet]. US Food and Drug Administration. 2019 [Accessed on 2024 Jan 8]. Available from: https:\/\/www.fda.gov\/media\/130801\/download#:~:text=This%20method%20will%20be%20used,drug%20substance%20or%20drug%20product.&text=N%2Dnitroso%2Ddi%2Dmethylamine%20(NDMA)%20impurity%20is,accuracy%20(HRAM)%20mass%20spectrometer"},{"key":"3202_CR58","unstructured":"US FDA. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of NDMA in Metformin Drug Substance and Drug Product [Internet]. US Food and Drug Administration. 2020 [Accessed on 2024 Jan 16]. Available from: https:\/\/www.fda.gov\/media\/134914\/download"},{"key":"3202_CR59","doi-asserted-by":"publisher","first-page":"340729","DOI":"10.1016\/j.aca.2022.340729","volume":"1239","author":"V Romero","year":"2023","unstructured":"Romero V, Sant\u2019Anna C, Lavilla I, Bendicho C. Fluorescent paper-based sensor integrated with headspace thin-film microextraction for the detection of acyclic N-nitrosamines following in situ photocatalytic decomposition. Anal Chim Acta. 2023;1239:340729.","journal-title":"Anal Chim Acta"},{"key":"3202_CR60","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.1021\/es070818l","volume":"41","author":"MH Plumlee","year":"2007","unstructured":"Plumlee MH, Reinhard M. Photochemical attenuation of N-nitrosodimethylamine (NDMA) and other nitrosamines in surface water. Environ Sci Technol. 2007;41:6170\u20136.","journal-title":"Environ Sci Technol"},{"key":"3202_CR61","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10337-013-2525-4","volume":"76","author":"R Peraman","year":"2013","unstructured":"Peraman R, Gowra CS, Reddy YP, Peruru KK. Stability-indicating RP-HPLC method for simultaneous determination of metformin hydrochloride and sitagliptin phosphate in dosage forms. Chromatographia. 2013;76:1153\u201362.","journal-title":"Chromatographia"},{"key":"3202_CR62","doi-asserted-by":"publisher","first-page":"121923","DOI":"10.1016\/j.ijpharm.2022.121923","volume":"623","author":"S Dharani","year":"2022","unstructured":"Dharani S, Mohamed EM, Khuroo T, Ali HI, Reddy IK, Rahman Z, et al. In-use stability assessment of FDA approved metformin immediate release and extended release products for N-Nitrosodimethylamine and dissolution quality attributes. Int J Pharm. 2022;623:121923.","journal-title":"Int J Pharm"},{"key":"3202_CR63","unstructured":"US FDA. GLUCOPHAGE (metformin hydrochloride) tablets, for oral use [Internet]. Reference ID: 4270422. 2018 [Accessed on 2023 Dec 8]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020357s034,021202s018lbl.pdf"},{"key":"3202_CR64","unstructured":"Chrominfo. Weight Variation Test for Tablets [Internet]. 2021 Jun. [Accessed on 2024 Jan 12] Available from: https:\/\/chrominfo.blogspot.com\/2018\/07\/weight-variation-test-for-tablets.html"},{"key":"3202_CR65","unstructured":"United States Pharmacopeial Convention. \u23291216\u232a Tablet friability. United States Pharmacopeia 43 \u2013 National Formulary 38 (USP 43\u2013NF 38). 2023;5:8137\u20138138."},{"key":"3202_CR66","unstructured":"United States Pharmacopeial Convention. \u2329701\u232a Disintegration. United States Pharmacopeia 43 \u2013 National Formulary 38 (USP 43\u2013NF 38). 2020;4:6940\u20136941."},{"key":"3202_CR67","unstructured":"Husain A. Practical Pharmaceutical Analytical Techniques, DARSHAN PUBLISHERS; Tamilnadu. 2021;1:67\u201369."},{"key":"3202_CR68","doi-asserted-by":"crossref","unstructured":"Djilali K, Maachi R, Mesbah ZA, Nasrallah N, Touzout N, Tahraoui H, et al. Breaking barriers in pharmaceutical analysis: Streamlined UV spectrometric quantification and stability profiling of haloperidol and methylparaben in liquid formulations. Anal Biochem [Internet]. 2024;695:115632. [Accessed on 2024 Mar 9] Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0003269724001763","DOI":"10.1016\/j.ab.2024.115632"},{"key":"3202_CR69","unstructured":"United States Pharmacopeial Convention. Metformin hydrochloride tablets (assay). United States Pharmacopeia 43 \u2013 National Formulary 38 (USP 43\u2013NF 38). 2020;2:2822\u20132823."},{"key":"3202_CR70","doi-asserted-by":"publisher","first-page":"115381","DOI":"10.1016\/j.jpba.2023.115381","volume":"229","author":"A Patel","year":"2023","unstructured":"Patel A, Jin C, Handzo B, Kalyanaraman R. Measurement of Moisture Content in Pharmaceutical Tablets by Handheld Near-Infrared Spectrometer: Adopting Quality by Design Approach to Analytical Method Lifecycle Management. J Pharm Biomed Anal. 2023;229:115381.","journal-title":"J Pharm Biomed Anal"},{"key":"3202_CR71","unstructured":"ICH Q1A(R2). STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS [Internet]. ICH HARMONISED TRIPARTITE GUIDELINE. 2023 [Accessed on 2024 Jan 18]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/Q1A%28R2%29%20Guideline.pdf"},{"key":"3202_CR72","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1139\/cjpp-2022-0265","volume":"101","author":"T Gulsun","year":"2022","unstructured":"Gulsun T, Izat N, Sahin S. Influence of permeability enhancers on the paracellular permeability of metformin hydrochloride and furosemide across Caco-2 cells. Can J Physiol Pharmacol. 2022;101:185\u201399.","journal-title":"Can J Physiol Pharmacol"},{"key":"3202_CR73","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1016\/j.xphs.2024.05.033","volume":"113","author":"D Lu","year":"2024","unstructured":"Lu D, Rege B, Raw A, Yang J, Alam K, Bode C, et al. Antioxidants had No Effects on the In-Vitro Permeability of BCS III Model Drug Substances. J Pharm Sci. 2024;113:2708\u201314.","journal-title":"J Pharm Sci"},{"key":"3202_CR74","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.xphs.2024.03.005","volume":"113","author":"YuY Chiang","year":"2024","unstructured":"Chiang YuY, Lu D, Rege B, Polli JE. Lack of Effect of Antioxidants on Biopharmaceutics Classification System (BCS) Class III Drug Permeability. J Pharm Sci. 2024;113:2215\u201322.","journal-title":"J Pharm Sci"},{"key":"3202_CR75","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/15376510903583711","volume":"20","author":"P Erkekoglu","year":"2010","unstructured":"Erkekoglu P, Baydar T. Evaluation of the protective effect of ascorbic acid on nitrite-and nitrosamine-induced cytotoxicity and genotoxicity in human hepatoma line. Toxicol Mech Methods. 2010;20:45\u201352.","journal-title":"Toxicol Mech Methods"},{"key":"3202_CR76","doi-asserted-by":"publisher","first-page":"e6025","DOI":"10.1002\/bmc.6025","volume":"38","author":"R Jain","year":"2024","unstructured":"Jain R, Aishwarya D, Wankhade S, Anupriya, Kumarasamy M, Peraman R. Identification and in vitro genotoxicity assessment of forced degradation products of glimepiride and glyburide using HEK cell-based COMET assay. Biomed Chromatogr. 2024;38:e6025.","journal-title":"Biomed Chromatogr"},{"key":"3202_CR77","unstructured":"ICH Q2(R1). VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY [Internet]. ICH HARMONISED TRIPARTITE GUIDELINE. 2005 [Accessed on 2024 Apr 18]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/Q2%28R1%29%20Guideline.pdf"},{"key":"3202_CR78","doi-asserted-by":"publisher","first-page":"115066","DOI":"10.1016\/j.jpba.2022.115066","volume":"222","author":"G Hao","year":"2023","unstructured":"Hao G, Hu R, Wang X, Gao P, Wang L, Jiang M, et al. N-Nitrosodimethylamine formation in metformin hydrochloride sustained-release tablets: Effects of metformin and hypromellose used in drug product formulation. J Pharm Biomed Anal. 2023;222:115066.","journal-title":"J Pharm Biomed Anal"},{"key":"3202_CR79","first-page":"80","volume":"2","author":"BS Rohokale","year":"2010","unstructured":"Rohokale BS, Jadhav V, Kadam VJ. Studies in process development of metformin HCL tablet dosage formulation. Int J Pharm Pharm Sci. 2010;2:80\u20132.","journal-title":"Int J Pharm Pharm Sci"},{"key":"3202_CR80","doi-asserted-by":"crossref","unstructured":"Charde MS, Jayani S, Pandey D. FORMULATION AND EVALUATION OF IMMEDIATE RELEASE TABLETS OF METFORMIN HYDROCHLORIDE ON LABORATORY SCALE. International Journal of Advances in Pharmaceutical Analysis. 2012;1:45.","DOI":"10.7439\/ijapa.v1i2.8"},{"key":"3202_CR81","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejpb.2009.04.005","volume":"73","author":"RA Shoukri","year":"2009","unstructured":"Shoukri RA, Ahmed IS, Shamma RN. In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets. Eur J Pharm Biopharm. 2009;73:162\u201371.","journal-title":"Eur J Pharm Biopharm"},{"key":"3202_CR82","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jddst.2018.05.014","volume":"46","author":"T Gulsun","year":"2018","unstructured":"Gulsun T, Cayli YA, Izat N, Cetin M, Oner L, Sahin S. Development and evaluation of terbutaline sulfate orally disintegrating tablets by direct compression and freeze drying methods. J Drug Deliv Sci Technol. 2018;46:251\u20138.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3202_CR83","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4103\/0250-474X.41452","volume":"70","author":"CM Setty","year":"2008","unstructured":"Setty CM, Prasad DVK, Gupta VRM, Sa B. Development of fast dispersible aceclofenac tablets: effect of functionality of superdisintegrants. Indian J Pharm Sci. 2008;70:180.","journal-title":"Indian J Pharm Sci"},{"key":"3202_CR84","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1039\/D4PM00259H","volume":"2","author":"I Ibrahim","year":"2025","unstructured":"Ibrahim I, Carroll M, Almudahka A, Mann J, Abbott A, Winge F, et al. Particle-based investigation of excipients stability: the effect of storage conditions on moisture content and swelling. RSC Pharmaceutics. 2025;2:369\u201386.","journal-title":"RSC Pharmaceutics"},{"key":"3202_CR85","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1016\/j.xphs.2023.09.003","volume":"112","author":"T Zelesky","year":"2023","unstructured":"Zelesky T, Baertschi SW, Foti C, Allain LR, Hostyn S, Franca JR, et al. Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective. J Pharm Sci. 2023;112:2948\u201364.","journal-title":"J Pharm Sci"},{"key":"3202_CR86","first-page":"178","volume":"3","author":"G Namdeo","year":"2013","unstructured":"Namdeo G. Shinde BNBSMDSPSDPS. Pharmaceutical Forced Degradation Studies with Regulatory Consideration. Asian J Res Pharm Sci. 2013;3:178\u201388.","journal-title":"Asian J Res Pharm Sci"},{"key":"3202_CR87","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.xphs.2021.01.011","volume":"110","author":"M Metry","year":"2021","unstructured":"Metry M, Shu Y, Abrahamsson B, Cristofoletti R, Dressman JB, Groot DW, et al. Biowaiver monographs for immediate release solid oral dosage forms: metformin hydrochloride. J Pharm Sci. 2021;110:1513\u201326.","journal-title":"J Pharm Sci"},{"key":"3202_CR88","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0378-5173(95)04259-8","volume":"128","author":"P Nicklin","year":"1996","unstructured":"Nicklin P, Keates AC, Page T, Bailey CJ. Transfer of metformin across monolayers of human intestinal Caco-2 cells and across rat intestine. Int J Pharm. 1996;128:155\u201362.","journal-title":"Int J Pharm"},{"key":"3202_CR89","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.3748\/wjg.v12.i25.4064","volume":"12","author":"N-N Song","year":"2006","unstructured":"Song N-N, Li Q-S, Liu C-X. Intestinal permeability of metformin using single-pass intestinal perfusion in rats. World J Gastroenterol: WJG. 2006;12:4064.","journal-title":"World J Gastroenterol: WJG"},{"key":"3202_CR90","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.mrrev.2017.05.004","volume":"773","author":"N Mahaye","year":"2017","unstructured":"Mahaye N, Thwala M, Cowan DA, Musee N. Genotoxicity of metal based engineered nanoparticles in aquatic organisms: A review. Mutat Res\/Rev Mutat Res. 2017;773:134\u201360.","journal-title":"Mutat Res\/Rev Mutat Res"},{"key":"3202_CR91","doi-asserted-by":"publisher","first-page":"402995","DOI":"10.1016\/j.mrgentox.2018.12.003","volume":"845","author":"M Mi\u0161\u00edk","year":"2019","unstructured":"Mi\u0161\u00edk M, Nersesyan A, Ropek N, Huber WW, Haslinger E, Knasmueller S. Use of human derived liver cells for the detection of genotoxins in comet assays. Mutat Res\/Genet Toxicol Environ Mutagen. 2019;845:402995.","journal-title":"Mutat Res\/Genet Toxicol Environ Mutagen"},{"key":"3202_CR92","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1007\/s00204-016-1767-y","volume":"90","author":"M Glei","year":"2016","unstructured":"Glei M, Schneider T, Schl\u00f6rmann W. Comet assay: an essential tool in toxicological research. Arch Toxicol. 2016;90:2315\u201336.","journal-title":"Arch Toxicol"},{"key":"3202_CR93","doi-asserted-by":"crossref","unstructured":"Gagne F, Lacaze E, Bony S, Devaux A, Gagn\u00e9 F. Genotoxicity. Biochemical Ecotoxicology. 2014;174\u2013186.","DOI":"10.1016\/B978-0-12-411604-7.00010-6"},{"key":"3202_CR94","first-page":"107","volume":"1","author":"W Lijinsky","year":"1987","unstructured":"Lijinsky W. Carcinogenicity and mutagenicity of N-nitroso compounds. Mol Toxicol. 1987;1:107\u201319.","journal-title":"Mol Toxicol"},{"key":"3202_CR95","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.mrgentox.2018.01.010","volume":"827","author":"Y Hong","year":"2018","unstructured":"Hong Y, Jeon HL, Ko KY, Kim J, Yi J-S, Ahn I, et al. Assessment of the predictive capacity of the optimized in vitro comet assay using HepG2 cells. Mutat Res\/Genet Toxicol Environ Mutagen. 2018;827:59\u201367.","journal-title":"Mutat Res\/Genet Toxicol Environ Mutagen"},{"key":"3202_CR96","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10565-011-9208-4","volume":"28","author":"HHJ Gerets","year":"2012","unstructured":"Gerets HHJ, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012;28:69\u201387.","journal-title":"Cell Biol Toxicol"},{"key":"3202_CR97","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1124\/dmd.31.8.1035","volume":"31","author":"S Wilkening","year":"2003","unstructured":"Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos. 2003;31:1035\u201342.","journal-title":"Drug Metab Dispos"},{"key":"3202_CR98","doi-asserted-by":"publisher","first-page":"128010","DOI":"10.1016\/j.jhazmat.2021.128010","volume":"426","author":"L Dong","year":"2022","unstructured":"Dong L, Jiang Z, Yang L, Hu F, Zheng W, Xue P, et al. The genotoxic potential of mixed nitrosamines in drinking water involves oxidative stress and Nrf2 activation. J Hazard Mater. 2022;426:128010.","journal-title":"J Hazard Mater"},{"key":"3202_CR99","doi-asserted-by":"publisher","first-page":"1615497","DOI":"10.1155\/2018\/1615497","volume":"2018","author":"M Valverde","year":"2018","unstructured":"Valverde M, Lozano-Salgado J, Fortini P, Rodriguez-Sastre MA, Rojas E, Dogliotti E. Hydrogen peroxide-induced DNA damage and repair through the differentiation of human adipose-derived mesenchymal stem cells. Stem Cells Int. 2018;2018:1615497.","journal-title":"Stem Cells Int"},{"key":"3202_CR100","unstructured":"Lu Y, Liu Y, Yang C. Evaluating in vitro DNA damage using comet assay. Cell Biology and Toxicology. 2007;5:53\u201364."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03202-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03202-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03202-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:04:11Z","timestamp":1758729851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03202-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":100,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["3202"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03202-8","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest with respect to the research, authorship, and publication of this article.The LC-ESI-HRMS method used for NDMA quantification has been published under Indian Patent Application No. 202331019501.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"218"}}